Ignite Creation Date:
2025-12-25 @ 3:22 AM
Ignite Modification Date:
2026-06-24 @ 10:51 AM
Study NCT ID:
NCT01397305
Status:
COMPLETED
Last Update Posted:
2020-09-09
First Post:
2011-05-25
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
An Extended Feasibility Phase I/II Study of Methylenetetrahydrofolate (Arfolitixorin) and Pemetrexed Single Agent, Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer
Sponsor:
Isofol Medical AB
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Rectal Cancer | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | 5,10-methylenetetrahydrofolate | View |
| None | neoadjuvant therapy | View |
| None | pemetrexed | View |
| None | Neoplasms | View |
| None | Rectal Neoplasms | View |
| None | Colorectal Neoplasms | View |
| None | Intestinal Neoplasms | View |
| None | Gastrointestinal Neoplasms | View |
| None | Digestive System Neoplasms | View |
| None | Neoplasms by Site | View |
| None | Rectal Diseases | View |
| None | Digestive System Diseases | View |
| None | Gastrointestinal Diseases | View |
| None | Intestinal Diseases | View |
| None | Pharmacologic Actions | View |
| None | Therapeutic Uses | View |
| None | Antineoplastic Agents | View |
| None | Enzyme Inhibitors | View |
| None | Molecular Mechanisms of Pharmacological Action | View |
| None | Folic Acid Antagonists | View |
| None | Antimetabolites, Antineoplastic | View |
| None | Antimetabolites | View |